Clinical Study on Evaluating the Safety and Effectiveness of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Third-line or Above Treatment
Latest Information Update: 30 Sep 2025
At a glance
- Drugs BCMA GPRC5D CAR-T cell therapy Guangzhou Bio-gene Technology (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Guangzhou Bio-gene Technology
Most Recent Events
- 30 Sep 2025 New trial record